Streamlining Radioembolization for Small HCC
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · May 11, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a treatment called radioembolization for patients with a type of liver cancer known as hepatocellular carcinoma (HCC). The study aims to see if we can safely skip a specific scan (called an MAA scan) before the treatment for certain patients. The researchers believe that by using specific selection criteria, they can streamline the process of radioembolization and make it easier for patients who meet these criteria.
To be eligible for this trial, patients should have HCC that is 5 centimeters or smaller and have certain types of blood vessel features within the tumor. They also need to have a specific level of liver function and meet other health criteria. Patients will be monitored closely throughout the trial to ensure their safety. This trial is not yet recruiting participants, but it is important for patients with small HCC to know about the potential for a more efficient treatment process if they meet the study criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HCC can be diagnosed by AASLD guideline
- • hepatocellular carcinoma 5cm or smaller
- • dysmorphic intratumoral vessels 3mm or smaller
- • Child-Pugh class A
- • ECOG 0 or 1
- • the following lab should be met. A. Leukocytes ≥ 1,000/µL and ≤ 20,000/µL B. Hemoglobin ≥ 6.0 g/dL (transfusion allowed to meet this criterion) C. Total bilirubin ≤ 2.0 mg/dL D. Platelet ≥ 40,000/µL E. International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants F. Aspartate transaminase (AST) ≤ 800 IU/L (i.e., ≤ 20X upper normal limit) G. Alanine transaminase (ALT) ≤ 800 IU/L (i.e., ≤ 20X upper normal limit) H. Creatinine ≤ 2.5 mg/dL (if patient is receiving hemodialysis, no upper limit of creatinine)
- Exclusion Criteria:
- • hepatic vein invasion on CT/MRI
- • hepatic vein enhancement on arterial phase of CT/MRI
- • TIPS
- • dysmorphic intratumoral vessels \> 3mm
- • main portal vein invasion
- • significant COPD or interstitial lung disease
- • biliary stent or bilioenteric anastomosis
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Goyang, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported